• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of gynaecological oncology >Relationship between chemotherapy with paclitaxel, cisplatin, vinorelbine and titanocene dichloride and expression of proliferation markers and tumour suppressor gene p53 in human ovarian cancer xenografts in nude mice.
【24h】

Relationship between chemotherapy with paclitaxel, cisplatin, vinorelbine and titanocene dichloride and expression of proliferation markers and tumour suppressor gene p53 in human ovarian cancer xenografts in nude mice.

机译：紫杉醇，顺铂，长春瑞滨和二茂钛二氯化物化疗与裸鼠人卵巢癌异种移植物中增殖标志物和抑癌基因p53表达的关系。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: In this study the relationship between therapy with paclitaxel, cisplatin, vinorelbine and titanocene dichloride and of the expression of proliferation markers (ki67 and S-phase fraction) and tumour suppressor gene p53 was analyzed using a human ovarian cancer xenograft model. METHODS: Biopsy material from one human ovarian cancer was expanded and transplanted into 102 nude mice. The mice were divided into six groups with different intraperitoneal treatments with paclitaxel, cisplatin, vinorelbine, titanocene dichloride and a control group treated with 0.9% saline solution. After the observation period the tumours were extracted and immunohistochemically stained with monoclonal antibodies against ki67 and p53. The S-phase-fraction was identified by flow cytometry. RESULTS: There where no statistically significant differences. Regarding the treatment groups, the vinorelbine-group showed the highest percentage (53.3%) and the titanocene dichloride-3x40 mg/kg-group the lowest percentage (7.1%) ofki67-positive specimens, whereas in the control group 35.7% of the specimens were positively stained for ki67. The results for the expression of p53 were similar. The vinorelbine-group had the highest percentage of p53-positive specimens (60%), in both titanocene-groups no specimen showed a positive staining for p53 and in the control group 7.1% of the specimens were positively stained for p53. The mean S-phase-fraction was 14.48% (SD +/- 3.98), no statistically significant relation between S-phase-fraction and expression of p53 (p = 0.883) or of ki67 (p = 0.351) could be shown. The change of tumour volume was independent of the results for ki67, p53 and the S-phase-fraction. CONCLUSION: Although, as previously published, a significant difference of tumour volume change occurred between the treatment groups, in this study we could not find a relation between this change of tumour volume and the expression of p53 or ki67. The absolute number of p53- and ki67-positive staining specimens was too small for statistical analysis, therefore the relevance of the differences between the different treatment groups and the control remains unclear. The results for the S-phase-fraction showed no correlation between the change of tumour volume, different treatment protocols or the expression of p53- and ki67. Our findings contribute to the controversy of the influence of chemotherapy on the expression of proliferation markers and p53.
机译：目的：在这项研究中，使用人类卵巢癌异种移植模型分析了紫杉醇，顺铂，长春瑞滨和二茂钛钛酸盐治疗与增殖标志物（ki67和S期组分）和抑癌基因p53表达之间的关系。方法：将一种人类卵巢癌的活检材料进行扩增，并移植到102只裸鼠中。将小鼠分为六组，分别用紫杉醇，顺铂，长春瑞滨，二茂钛二氯化钛进行不同的腹膜内治疗，而对照组则用0.9％的盐溶液处理。观察期后，提取肿瘤并用针对ki67和p53的单克隆抗体进行免疫组织化学染色。通过流式细胞术鉴定S期分数。结果：没有统计学上的显着差异。在治疗组中，长春瑞滨组的ki67阳性标本的百分比最高（53.3％），二氯化钛三茂铁3×40 mg / kg组的最低百分比（7.1％），而对照组中标本的比例为35.7％被ki67染色阳性。 p53表达的结果相似。长春瑞滨组的p53阳性标本百分比最高（60％），在两个钛茂组中，没有标本显示p53阳性，而对照组的7.1％标本中p53阳性。平均S相分数为14.48％（SD +/- 3.98），S相分数与p53（p = 0.883）或ki67（p = 0.351）的表达之间无统计学意义的相关性。肿瘤体积的变化与ki67，p53和S期分数的结果无关。结论：尽管如前所述，治疗组之间的肿瘤体积变化存在显着差异，但在这项研究中，我们未能发现肿瘤体积变化与p53或ki67表达之间的关系。 p53和ki67阳性染色样本的绝对数量太少，无法进行统计分析，因此，尚不清楚不同治疗组与对照组之间差异的相关性。 S期分数的结果显示，肿瘤体积的变化，不同治疗方案或p53和ki67的表达之间无相关性。我们的发现促成了化学疗法对增殖标志物和p53表达的影响的争议。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号